Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Expected to Post Q2 2022 Earnings of ($0.68) Per Share

Olema Pharmaceuticals, Inc. (NASDAQ:OLMAGet Rating) – Research analysts at Jefferies Financial Group lowered their Q2 2022 earnings per share (EPS) estimates for shares of Olema Pharmaceuticals in a note issued to investors on Monday, May 9th. Jefferies Financial Group analyst M. Yee now forecasts that the company will post earnings per share of ($0.68) for the quarter, down from their prior forecast of ($0.65). Jefferies Financial Group also issued estimates for Olema Pharmaceuticals’ Q3 2022 earnings at ($0.73) EPS, Q4 2022 earnings at ($0.81) EPS, FY2022 earnings at ($2.81) EPS and FY2023 earnings at ($3.65) EPS.

Several other analysts have also commented on OLMA. Zacks Investment Research raised shares of Olema Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, April 29th. HC Wainwright began coverage on shares of Olema Pharmaceuticals in a research report on Monday, February 28th. They set a “neutral” rating for the company.

NASDAQ:OLMA opened at $2.04 on Thursday. Olema Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $32.77. The business has a 50-day simple moving average of $3.71. The stock has a market capitalization of $82.31 million, a price-to-earnings ratio of -1.13 and a beta of 2.54.

Olema Pharmaceuticals (NASDAQ:OLMAGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01).

Large investors have recently modified their holdings of the stock. Dupont Capital Management Corp acquired a new position in Olema Pharmaceuticals in the 4th quarter worth approximately $173,000. Renaissance Technologies LLC acquired a new position in Olema Pharmaceuticals in the 3rd quarter worth approximately $2,698,000. Two Sigma Investments LP acquired a new position in Olema Pharmaceuticals in the 3rd quarter worth approximately $2,742,000. Geode Capital Management LLC increased its holdings in Olema Pharmaceuticals by 118.9% in the 3rd quarter. Geode Capital Management LLC now owns 465,287 shares of the company’s stock worth $12,823,000 after buying an additional 252,765 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Olema Pharmaceuticals by 2.0% in the 3rd quarter. Wellington Management Group LLP now owns 1,649,204 shares of the company’s stock worth $45,451,000 after buying an additional 32,906 shares during the period.

About Olema Pharmaceuticals (Get Rating)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Read More

Earnings History and Estimates for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.